中文摘要：

目的探讨帕金森病患者伴发幻觉的发生率及与非运动症状之间的关系。方法连续收集2012年2月至2013年2月就诊于北京天坛医院神经内科的105例病程为10年以内的帕金森病患者,采用神经精神问卷（NPI）中第2项症状的＂有无＂分为有幻觉组和无幻觉组,收集患者一般资料、用药情况,完成多种非运动症状的评价。结果 （1）105例帕金森病患者幻觉的发生率为11.4%;（2）有幻觉组病程[（4.08±2.47）年]长于无幻觉组[（2.56±2.24）年],差异接近具有统计学意义（P=0.062）,两组性别、年龄及起病年龄无显著差异（P〉0.05）,有幻觉组H-Y分期及UPDRSⅢ评分[（2.63±1.13）期,（38.58±18.10）分]明显高于无幻觉组[（1.90±0.69）期,（25.07±14.32）分]（P〈0.05）;（3）有幻觉组与无幻觉组抑郁、焦虑、疲劳、睡眠障碍、日间思睡及快速眼动睡眠期行为障碍的发生率具有显著差异（91.7%vs.60.2%,66.7%vs.30.1%,100.0%vs.66.3%,100.0%vs.62.4%,66.7%vs.34.4%,42.8%vs.10.7%,P〈0.05）,有幻觉组蒙特利尔认知评估量表（MoCA）评分明显低于无幻觉组（20.5分vs.24.0分,P〈0.05）,有幻觉组汉密尔顿抑郁量表（HAMD）、汉密尔顿抑郁量表（HAMA）、疲劳量表（FS-14）、匹兹堡睡眠质量指数量表（PSQI）及爱泼沃斯思睡量表（ESS）的评分和自主神经症状量表（SCOPA-AUT）中症状的个数均明显高于无幻觉组（23.0分vs.10.0分,17.5分vs.7.0分,10.0分vs.8.0分,10.0分vs.6.0分,7.5分vs.4.0分,14.0个vs.8.0个）,其中有幻觉组实际睡眠时间和睡眠效率明显低于无幻觉组[（5.96±1.95）h vs.（6.92±1.39）h,（76.04±16.04）%vs.（85.52±14.38）%,P〈0.05],有幻觉组消化系统症状和心血管系统症状的个数明显多于无幻觉组（P〈0.05）;两组简易智力状态检查量表（MMSE）、改良淡漠评定量表（MAES）的评分无显著差异（P〉0.05）;（4）两组左旋多巴等效剂量（LDE）无显著差异?

英文摘要：

Objective To investigate the incidence and relationship with other non-motor symptoms of Parkinson’s Disease （PD） patients with hallucinations. Methods 105 PD patients with disease duration within ten years were recruited. The patients were divided into hallucination group and non-hallucination group according to the second item of Neuropsychiatric Inventory （NPI）. The patients were collected for general information and the use of medicine, and a comparison study was conducted by using PD related non-motor symptoms scales. Results （1）12 cases （11.4%） of PD patients were accompanied by hallucinations;（2）The disease duration in hallucination group, 4.08±2.47 years, was longer than that in non-hallucination group,2.56±2.24 years,with no significance （P=0.062）, and two groups were not different in gender, age and age at onset （P〈0.05）, Hoehn-Yahr staging and the score of Unified Parkinson Disease Rating Scale （UPDRS） Ⅲ in hallucination group （stage 2.63±1.13, 38.58±18.10） was significantly higher than that in non-hallucination group （stage 1.90±0.69, 25.07±14.32）（P＆lt;0.05）;（3） The incidences of depression, anxiety, fatigue, sleep disorders, daytime somnolence and RBD were all significantly higher in hallucination group than that in non-hallucination group （91.7%vs. 60.2%, 66.7%vs. 30.1%, 100.0%vs. 66.3%, 100.0% vs. 62.4%, 66.7% vs. 34.4%, 42.8% vs. 10.7%, P＆lt;0.05）; the scores of Montreal Cognitive Assessment, Hamilton Depression Scale, Hamilton Anxiety Scale, Fatigue Scale-14, Pittsburgh Sleep Quality＆amp;nbsp;Index, Epworth Sleeping Scale and the number of autonomic dysfunctions assessed by The Scale for Outcomes in PD for Autonomic Symptoms were all significantly different between hallucination group and non-hallucination group （20.5 vs. 24.0, 23.0 vs. 10.0, 17.5 vs. 7.0, 10.0 vs. 8.0, 10.0 vs. 6.0, 7.5 vs. 4.0, 14.0 vs. 8.0, P＆lt;0.05） expect Mini-Mental State Examination and Modified Apathy Estimate Scale （P〈0.05）, and actual sle